Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Measures Would Be Necessary if Generic Brands Continue to Increase Due to Joint Development: MHLW Official Jo
June 18, 2015
- PAFSC 2nd Committee Supports Approval of Olanexidine, New Indication for Zosyn
June 18, 2015
- Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
- MHLW Designates Ceritinib as Orphan Drug
June 17, 2015
- Govt Working Group Calls for Switching Contract Manufacturing of Long-Listed Drugs to Generic Production
June 16, 2015
- Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
- Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
- LDP Compiles Proposal for Govt Growth Strategy, Including Target for Sakigake System
June 12, 2015
- Abe of JPA Proposes Exempting Ordinary Pharmacies from Medical Fee Cut Rule: Chuikyo
June 12, 2015
- Shiozaki’s Pitch on 80% Generic Target by FY2020 Fails to Resonate
June 11, 2015
- NHI Price Revision in FY2017 and Annual NHI Price Revision Should Be Discussed Separately: Shirakawa
June 11, 2015
- Chuikyo Begins Discussions on FY2016 NHI Pricing Reform; Drug Pricing Organization to Present Views at Next Meeting
June 11, 2015
- PAFSC Second Committee to Discuss Olanexidine, Zosyn on June 17
June 10, 2015
- LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
- Kaketsuken Suspends Shipments of 12 Products Due to Modifications of Approved Manufacturing Procedures
June 9, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 25 - June 7
June 8, 2015
- MHLW’s Jo Urges Generic Makers to Formulate Careful Investment Plans
June 8, 2015
- Govt Working Group Suspicious about Supply Limitation Hindering Generic Goal
June 8, 2015
- PAFSC 1st Committee Backs Approval of Lilly’s GLP-1 Receptor Agonist Dulaglutide
June 8, 2015
- 8 Members of PAFSC’s Pharmaceutical Affairs Council to Be Ousted for Violating COI Rules
June 8, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…